8-K filing — Kalaris Therapeutics, Inc. (KLRS)
Filed: 2026-08-11 AccNo: 0001193125-26-343477 Size: 201 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Kalaris Therapeutics Appoints Liisa Bayko CFO
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 12:03 PM
- Checked
- Jul 20, 2026, 12:03 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Kalaris Therapeutics Q2 EPS $(0.48) Beats $(0.49) Estimate
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 21.31 percent increase over losses of $(0.61) per share
Read original at benzingaSDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders
Abbott Cooper PLLC is investigating potential fiduciary duty breaches by the board of directors of Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.). The investigation targets stockholders who continuously held shares since prior to August 19, 2025. Similar investigations are also underway for Kalaris Therapeutics (formerly AlloVir) and Abundia Global Impact Group (formerly Houston American Energy Corp.).
Read original at globenewswire-inc